SCHEDULE 13G/A: Millennium Management Entities Disclose Passive Stake Below 5% in Verve Therapeutics

Integrated Core Strategies (US) LLC and Millennium Management entities, including Israel A. Englander, have filed an amended Schedule 13G disclosing beneficial ownership of less than 5% in Verve Therapeutics, Inc. as of December 31, 2024.

Summary

• Integrated Core Strategies (US) LLC beneficially owns 2,864,133 shares of Verve Therapeutics, Inc. Common Stock, representing 3.4% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively beneficially own 3,919,131 shares of Verve Therapeutics, Inc. Common Stock, representing 4.6% of the class.
• All reporting persons have shared voting and shared dispositive power over their respective reported shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to previously reported beneficial ownership.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of passive investment by institutional entities in a publicly traded company, common in the financial industry for transparency regarding significant ownership stakes.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership stakes, confirming a passive investment approach by the reporting entities.

Key Dates

Keywords

Verve Therapeutics, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing